TRMT44

Across TCGA pan-cancer cohorts, TRMT44 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRMT44 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TRMT44 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT44 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where TRMT44 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.245	0.784	<.001	10	view →
PDAC	OS	Quartile	All	0.659	0.957	.016	7	view →
UCEC	DFS	Median	All	0.943	0.774	.033	2	view →
LSCC	OS	Median	All	0.770	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRMT44–LUAD (OS)

Open the LUAD breakdown →